AstraZeneca Plc has negotiated rights to an early clinical stage therapeutic designed to remove amyloid fibril deposits in the heart. The agreement, with Neurimmune AG of Switzerland, relates to NI006, a monoclonal antibody in Phase 1b for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM), a systemic condition that can lead to progressive heart failure.
The disease is caused by aging or genetic mutations resulting in a misfolding of the transthyretin protein and an accumulation as amyloid fibrils in the cardiac myocardium.